Objectives and methods of iron chelation therapy.

Area of Science:

• Hematology
• Pharmacology
• Molecular Biology

Background:

• Iron homeostasis is crucial for health, but chronic anemias can lead to iron overload and toxicity.
• Current iron chelating therapies, like deferoxamine (DFO), are effective but have limitations including cost and administration requirements.
• Existing oral chelators, such as deferiprone (L1), show potential but have efficacy and safety concerns.

Purpose of the Study:

• To review the current landscape of iron chelating therapies for chronic anemias.
• To explore the development and potential of novel orally effective iron chelators.
• To investigate innovative strategies for iron chelation, including combination therapies.

Main Methods:

• Review of recent literature on molecular control of iron homeostasis.
• Screening and evaluation of candidate iron chelating compounds in animal models.
• Analysis of clinical trial data for existing and novel iron chelators.

Main Results:

• Deferoxamine (DFO) remains a cornerstone therapy, but its limitations necessitate alternatives.
• Several novel oral iron chelators, including deferiprone (L1), pyridoxal isonicotinoyl hydrazone (PIH), and bishydroxy-phenyl thiazole, have emerged.
• Deferiprone (L1) shows promise but has limitations in achieving negative iron balance and potential hepatotoxicity concerns.

Conclusions:

• There is a significant need for improved, orally effective iron chelators.
• Novel oral chelators may not replace DFO but can complement it, improving patient compliance and outcomes.
• Combination or alternating use of DFO with oral chelators presents a promising strategy for managing iron overload in chronic anemias.